• Citer

Low doses of anti-CD3, ciclosporin A and the vitamin D analogue, TX527, synergise to delay recurrence of autoimmune diabetes in an islet-transplanted NOD mouse model of diabetes.

par Baeke, F.;Van Belle, Tom L;Takiishi, Tatiana ;Ding, Lei;Korf, Hannelie;Laureys, Jos;Gysemans, C;Mathieu, Chantal
Référence Diabetologia, 55, 10, page (2723-2732)
Publication Publié, 2012-10

Article révisé par les pairs

• Détails
• Contenu

Résumé :

Anti-CD3 monoclonal antibodies remain the most promising immune therapy for reversing recent-onset type 1 diabetes. However, current clinical trials have revealed their major drawback, namely the narrow therapeutic window in which low doses are ineffective and higher doses that preserve functional beta cell mass cause side effects. Strategies that sidestep these limitations while preserving or improving anti-CD3's therapeutic efficiency are essential. We hypothesised that combining a potent vitamin D(3) analogue (TX527), ciclosporin A (CsA) and anti-CD3 would act to lower the dose while maintaining or even boosting therapeutic efficacy to counteract autoimmune destruction of transplanted islets.